🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Mexico expects U.S. response to AstraZeneca vaccine request on Friday

Published 03/16/2021, 11:53 AM
Updated 03/16/2021, 12:45 PM
© Reuters. Outbreak of the coronavirus disease (COVID-19) in Belgrade
PFE
-
AZN
-
BNTX
-

By Anthony Esposito and Raul Cortes

MEXICO CITY (Reuters) - The United States should respond by Friday to Mexico's request to share doses of AstraZeneca (NASDAQ:AZN)'s COVID-19 vaccine it has in stock, Foreign Minister Marcelo Ebrard said on Tuesday.

Reuters reported this week that Mexico had asked for doses of the British-developed vaccine, since it has yet to be approved for use in the United States.

"I'd say we've made good progress, but the details, figures, provisions, won't be known until Friday. We requested as many (AstraZeneca doses) as possible and we will have the answer on Friday," said Ebrard.

Mexico's President Andres Manuel Lopez Obrador asked U.S. President Joe Biden for a vaccine "loan" during a virtual meeting on March 1, after Mexico's vaccine strategy was knocked off course by a delay in deliveries of the vaccine developed by Pfizer Inc (NYSE:PFE) and German partner BioNTech SE (NASDAQ:BNTX).

"We are hoping for the help, support and solidarity of the U.S. government. I can confirm that in a month and a half, before the end of April, we will have (vaccinated) all the adults over 60 years of age," Lopez Obrador said at a regular news conference on Tuesday.

The delays in deliveries have set back Mexico's vaccination plans by at least a month. Previously, Lopez Obrador had said all senior citizens would be vaccinated by the end of March.

"The president has been clear that our priority is vaccinating the American people and that if we have surplus vaccines from that effort we will look for ways to share them," a spokesperson for the White House National Security Council said when asked about Ebrard's comments.

The official did not directly address the question of whether the U.S. government would respond by Friday, as Ebrard said.

© Reuters. Arrival of a batch of the AstraZeneca's COVID-19 vaccine, in Mexico City

Mexico will also sign a contract on Tuesday with China's Sinovac Biotech Ltd to purchase 20 million COVID-19 vaccine doses, Ebrard said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.